Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA 94143, USA.
Support Care Cancer. 2011 Mar;19(3):353-61. doi: 10.1007/s00520-010-0824-y. Epub 2010 Feb 16.
The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the relationships between demographic, clinical, and symptom characteristics of children with cancer and generic and disease-specific dimensions of HRQOL.
Patients (n = 61) were predominantly male (52.5%), minority (63.9%), and 14.7 years of age. Children completed the Memorial Symptom Assessment Scale for 10- to 18-year olds, the PedsQL™ Generic and Cancer Modules, and the Karnofsky Performance Status (KPS) scale 1 week after the start of a chemotherapy cycle.
The mean number of symptoms per patient was 10.6. Compared with the normative sample, children with cancer reported significantly lower scores for the total scale and all of the subscales except emotional and social functioning. No significant differences were found between any demographic characteristics and total or subscale scores on the generic or disease-specific measures of HRQOL. Lower KPS scores were associated with poorer generic and disease-specific HRQOL scores. In addition, a higher number of symptoms was associated with poorer generic and disease-specific HRQOL scores. Finally, higher symptom distress scores were associated with poorer generic and disease-specific HRQOL scores.
Among the demographic, clinical, and symptom characteristics studied, poorer functional status and higher symptom burden were associated with significant decreases in HRQOL in children who received myelosuppressive chemotherapy.
本研究旨在比较接受骨髓抑制性化疗后 1 周的儿童在通用健康相关生活质量（HRQOL）量表上的总分和子量表评分与健康儿童的正常数据，并描述儿童癌症患者的人口统计学、临床和症状特征与通用和疾病特异性 HRQOL 维度之间的关系。
患者（n=61）主要为男性（52.5%）、少数民族（63.9%），年龄为 14.7 岁。儿童在化疗周期开始后 1 周内完成了 10-18 岁的 Memorial 症状评估量表、PedsQL™通用和癌症模块以及 Karnofsky 表现状态（KPS）量表。
每位患者的平均症状数为 10.6 个。与正常样本相比，癌症儿童报告的总分和除情绪和社会功能外的所有子量表得分均显著较低。在通用或疾病特异性 HRQOL 测量的任何人口统计学特征与总分或子量表评分之间均未发现显著差异。较低的 KPS 评分与通用和疾病特异性 HRQOL 评分较差相关。此外，症状数量较高与通用和疾病特异性 HRQOL 评分较差相关。最后，较高的症状困扰评分与通用和疾病特异性 HRQOL 评分较差相关。
在研究的人口统计学、临床和症状特征中，较差的功能状态和较高的症状负担与接受骨髓抑制性化疗的儿童 HRQOL 显著下降相关。
